Pneumagen Company
Pneumagen develops glycan targeted carbohydrate binding modules (CBMs) for respiratory tract infections ) and cancer.
Technology:
Anti-infective Drugs
Industry:
Gene therapy
Headquarters:
Saint Andrews, Fife, United Kingdom
Founded Date:
2016
Employees Number:
1-10
Investors Number:
2
Total Funding:
£4M
Estimated Revenue:
$1M to $10M
Last Funding Type:
Venture - Series Unknown
Register and Claim Ownership